Results 121 to 130 of about 950,583 (268)

COMPARISON OF HCV RNA AND HCV CORE ANTIGEN IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS [PDF]

open access: yes, 2014
Ankarali, Handan Camdeviren/0000-0002-3613-0523; Karabay, Oguz/0000-0003-0502-432XWOS: 000364114800009Background: Anti-HCV test is currently used in the diagnosis of hepatitis C, while hepatitis C virus ribonucleic acid (HCV RNA) is used in the ...
Özdemir, Fatma   +5 more
core   +2 more sources

The best anti-HCV S/Co values for reflecting HCV infection in a university hospital in the eastern part of Turkey

open access: yesJournal of Infection in Developing Countries
Introduction: The measurement of hepatitis C virus (HCV) RNA is a test that requires high cost, advanced technique, and qualified personnel. Diagnosis and treatment of patients may be delayed due to the high rate of false-positive results.
Bülent Dabanlıoğlu   +3 more
doaj   +1 more source

Longitudinal changes in readily available inflammatory markers before and after switching to integrase inhibitor‐based antiretroviral therapy in Virologically suppressed people living with HIV: A Nationwide real‐world cohort study

open access: yesHIV Medicine, EarlyView.
Abstract Background Persistent immune activation and systemic inflammation remain key features of chronic HIV infection despite sustained virological suppression under antiretroviral therapy (ART), contributing to excess non‐AIDS morbidity and mortality.
Stelios F. Assimakopoulos   +71 more
wiley   +1 more source

Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study.

open access: yesPLoS ONE, 2015
BackgroundUnderstanding the patterns of HCV RNA levels during acute hepatitis C virus (HCV) infection provides insights into immunopathogenesis and is important for vaccine design.
Behzad Hajarizadeh   +19 more
doaj   +1 more source

HCV RNA and age of infection.

open access: yes, 2014
HCV RNA and age of infection.
Ashwin Balagopal (19837)   +6 more
core   +1 more source

Pregnancy and neonatal outcomes after prenatal exposure to dolutegravir: Data from a European cohort collaboration

open access: yesHIV Medicine, EarlyView.
Abstract Objective We aimed to assess ‘real‐world’ pregnancy and neonatal outcomes following prenatal dolutegravir (DTG) use in a European setting. Methods We conducted a pooled analysis of individual‐patient data from seven observational studies. Pregnancies with DTG exposure any time from the periconception period (≤6 completed gestational weeks ...
Rebecca Sconza   +22 more
wiley   +1 more source

Prevalence of HPgV-2 RNA in HCV and non-HCV infected groups.

open access: yes, 2015
*P-value of differences in HPgV-2 RNA (top) and antibody (bottom) prevalence between reference and comparison groups. Index case (HCV Ab+ /NAT+) has been excluded from totals screened.Prevalence of HPgV-2 RNA in HCV and non-HCV infected groups.
Matthew Frankel (836755)   +13 more
core   +1 more source

Preventing infections after CD19‐directed chimeric antigen receptor T‐cell therapies for lymphoma: a consensus practice statement

open access: yesInternal Medicine Journal, EarlyView.
Abstract Chimeric antigen receptor (CAR) T‐cell therapies directed against cluster of differentiation 19 (CD19) are a standard of care for relapsed or refractory B‐cell lymphomas. Infection is the leading cause of non‐relapse mortality, and this risk may persist for years after CAR T‐cell receipt.
Aine Hurley   +15 more
wiley   +1 more source

HCV RNA载量与肝脏组织损伤的关系

open access: yesZhongguo shiyan zhenduanxue, 2011
目的探讨丙型肝炎病毒(HCV)RNA复制水平与肝功能丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)之间的相互关系。方法收集1182例疑似丙肝病人血清标本,采用荧光定量聚合酶链反应(FQ-PCR)检测HCV RNA,利用酶动力法测定ALT、AST,采用ELISA测定抗HCV抗体。数据采用SPSS16.0统计软件处理。结果病人血清样本中,HCV RNA阳性801例(64.8%),其中抗HCV阳性766例(95.6%);HCV RNA阴性381例(32.2%),其中抗HCV阳性100例(26.2%)
丁柳   +6 more
doaj  

NGS of HCV biopsy RNA.

open access: yes, 2013
Extracted and pooled (×6) HCV infected biopsy RNA was reverse transcribed and amplified prior to Illumina NGS and mapped to the HCV reference 3a.NZL. NC_0009824 (Los Alamos HCV database).
Paul Kellam (6413)   +12 more
core   +1 more source

Home - About - Disclaimer - Privacy